Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Ohio State University
2006
mi
from 98109
Columbus, OH
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Ohio State University
2006
mi
from 98109
Columbus, OH
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Drexel University College of Medicine
2373
mi
from 98109
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Drexel University College of Medicine
2373
mi
from 98109
Philadelphia, PA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Inova Fairfax
2316
mi
from 98109
Falls Church, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Inova Fairfax
2316
mi
from 98109
Falls Church, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Sentara Heart Hospital
2430
mi
from 98109
Norfolk, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Sentara Heart Hospital
2430
mi
from 98109
Norfolk, VA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
2
mi
from 98109
Seattle, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Heart Clinics Northwest
228
mi
from 98109
Spokane, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
Heart Clinics Northwest
228
mi
from 98109
Spokane, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
The Vancouver Clinic
139
mi
from 98109
Vancouver, WA
S-ICD® System IDE Clinical Study
S-ICD® System Clinical Investigation
Status: Archived
Updated: 1/1/1970
The Vancouver Clinic
139
mi
from 98109
Vancouver, WA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Clinical Trial Facility
2485
mi
from 98109
Boston, MA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2485
mi
from 98109
Boston, MA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Hematology Oncology Associates of the Quad Cities
1609
mi
from 98109
Bettendorf, IA
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
1609
mi
from 98109
Bettendorf, IA
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
Status: Archived
Mayo Clinic College of Medicine
1450
mi
from 98109
Rochester, MN
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis
Status: Archived
Updated: 1/1/1970
Mayo Clinic College of Medicine
1450
mi
from 98109
Rochester, MN
Clinical Trial to Assess the Early Effects of RVX000222 on the Changes of Lipid and Coronary Plaque in Patients With Recent Acute Coronary Syndrome
Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trials for the Assessment of Lipid and Coronary Plaque Changes With RVX000222 in Patients With Acute Coronary Syndrome Events
Status: Archived
West Shore Cardiology
1761
mi
from 98109
Muskegon, MI
Clinical Trial to Assess the Early Effects of RVX000222 on the Changes of Lipid and Coronary Plaque in Patients With Recent Acute Coronary Syndrome
Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trials for the Assessment of Lipid and Coronary Plaque Changes With RVX000222 in Patients With Acute Coronary Syndrome Events
Status: Archived
Updated: 1/1/1970
West Shore Cardiology
1761
mi
from 98109
Muskegon, MI
Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Feasibility and Safety of Same-Day Discharge of Troponin Negative Patients After Coronary PTCA Via the Transfemoral Approach
Status: Archived
Piedmont Hospital
2177
mi
from 98109
Atlanta, GA
Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Feasibility and Safety of Same-Day Discharge of Troponin Negative Patients After Coronary PTCA Via the Transfemoral Approach
Status: Archived
Updated: 1/1/1970
Piedmont Hospital
2177
mi
from 98109
Atlanta, GA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
711
mi
from 98109
Santa Clara, CA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
2429
mi
from 98109
Newington, CT
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2429
mi
from 98109
Newington, CT
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
2322
mi
from 98109
Washington,
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2322
mi
from 98109
Washington,
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
2550
mi
from 98109
Celebration, FL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2550
mi
from 98109
Celebration, FL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
1773
mi
from 98109
Centralia, IL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1773
mi
from 98109
Centralia, IL
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
1933
mi
from 98109
Detroit, MI
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1933
mi
from 98109
Detroit, MI
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
2353
mi
from 98109
Albany, NY
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2353
mi
from 98109
Albany, NY
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
Efficacy and Safety Study of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM)for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolveâ„¢ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
Isovue in Peripheral Digital Subtraction Angiography
A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)
Status: Archived
Bracco Diagnostics Inc
2383
mi
from 98109
Princeton, NJ
Isovue in Peripheral Digital Subtraction Angiography
A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)
Status: Archived
Updated: 1/1/1970
Bracco Diagnostics Inc
2383
mi
from 98109
Princeton, NJ
Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency
Status: Archived
Center for Curative & Palliative Wound Care Calvary Hospital
2405
mi
from 98109
New York, NY
Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency
Status: Archived
Updated: 1/1/1970
Center for Curative & Palliative Wound Care Calvary Hospital
2405
mi
from 98109
New York, NY
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Partners HealthCare
2485
mi
from 98109
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Partners HealthCare
2485
mi
from 98109
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
VA Boston Health Care System
2485
mi
from 98109
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
VA Boston Health Care System
2485
mi
from 98109
Boston, MA
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
Heart Biomarker Evaluation in Apnea Treatment
Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
2024
mi
from 98109
Cleveland, OH
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
University of Miami Hospital
2730
mi
from 98109
Miami, FL
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
2730
mi
from 98109
Miami, FL
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)
A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
2326
mi
from 98109
Baltimore, MD
Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study
Status: Archived
The Vascular Group, PLLC
2348
mi
from 98109
Albany, NY
Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study
Status: Archived
Updated: 1/1/1970
The Vascular Group, PLLC
2348
mi
from 98109
Albany, NY
Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?
Is Omega-3 Fatty Acid RBC Saturation Product Dependent?
Status: Archived
Bucci Laser Vision Institute
2298
mi
from 98109
Wilkes-Barre, PA
Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?
Is Omega-3 Fatty Acid RBC Saturation Product Dependent?
Status: Archived
Updated: 1/1/1970
Bucci Laser Vision Institute
2298
mi
from 98109
Wilkes-Barre, PA
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
1980
mi
from 98109
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
1980
mi
from 98109
Franklin, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Vanderiblt University Medical Center
1971
mi
from 98109
Nashville, TN
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
1971
mi
from 98109
Nashville, TN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1116
mi
from 98109
Phoenix, AZ
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
1782
mi
from 98109
Little Rock, AR
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1782
mi
from 98109
Little Rock, AR
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
1020
mi
from 98109
Denver, CO
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1020
mi
from 98109
Denver, CO
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
2432
mi
from 98109
New Haven, CT
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2432
mi
from 98109
New Haven, CT
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
2322
mi
from 98109
Washington,
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2322
mi
from 98109
Washington,
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
2717
mi
from 98109
Fort Lauderdale, FL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2717
mi
from 98109
Fort Lauderdale, FL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
2679
mi
from 98109
Honolulu, HI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2679
mi
from 98109
Honolulu, HI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
399
mi
from 98109
Meridian, ID
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
399
mi
from 98109
Meridian, ID
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
1725
mi
from 98109
Evanston, IL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1725
mi
from 98109
Evanston, IL
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
1879
mi
from 98109
Anderson, IN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1879
mi
from 98109
Anderson, IN